Newly developed retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable excitement within the healthcare community. Initial clinical studies have demonstrated impressive reductions in body weight and improvements in health markers for individuals with excess weight . Scientists believe this … Read More